2. 多肽产品
  3. 多肽及其衍生物
  4. nNIF peptide

nNIF peptide 是一种内源性多肽，可在人脐带和新生儿血液中检测到。nNIF peptide 特异性抑制中性粒细胞形成中性粒细胞胞外诱捕网 (NETs)，同时不干扰中性粒细胞的其他关键免疫功能。nNIF peptide 可用于 COVID-19 急性呼吸窘迫综合征、多微生物败血症和新生儿感染性腹膜炎的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

nNIF peptide

nNIF peptide Chemical Structure

CAS No. : 1644397-65-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of nNIF peptide:

nNIF peptide 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis[1][2][3].

体外研究
(In Vitro)

nNIF peptide (1 nM; 1-2 h) 可强效阻断 COVID-19 患者血浆诱导的、从健康成人供体分离的原代中性粒细胞 (PMNs) 的中性粒细胞胞外诱捕网 (NET) 形成[1]。
nNIF peptide (1 nM; 1.5 h) 不会改变经 PMA (HY-18739) 刺激的、从 7 至 10 日龄远交系 Swiss Webster 小鼠脾脏分离的中性粒细胞中活性氧的生成[3]。
nNIF peptide (1 nM; 3 h) 不会改变 7~10 日龄远交系 Swiss Webster 小鼠脾脏分离中性粒细胞对荧光标记 E. coli 生物颗粒的吞噬作用[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

nNIF peptide 相关抗体:
体内研究
(In Vivo)

nNIF peptide (0.1-1 mg/kg；静脉注射；给药 2 次) 可呈剂量依赖性地改善 Swiss Webster 小鼠脓毒症模型的存活率，其中 0.5 mg/kg 和 1 mg/kg 剂量组的 6 天存活率分别达到 70% 和 73%，同时还能减少 NET 形成、降低疾病严重程度以及腹膜 TNF-α 水平[2]。
nNIF peptide (1 mg/kg；静脉注射；给药 2 次) 作为亚优化 Meropenem (HY-13678) 的辅助治疗，可使 Swiss Webster 小鼠脓毒症模型的 6 天存活率提升至 90%，同时改善疾病严重程度并使晚期细菌 CFU 水平恢复正常[2]。
nNIF peptide (10 mg/kg；腹腔注射；2 次给药) 可显著将盲肠浆液诱导感染性腹膜炎新生小鼠的存活率提升至 47%，同时减少腹膜中性粒细胞胞外诱捕网 (NET) 形成、促炎细胞因子水平及循环血小板-中性粒细胞聚集体，并增加腹膜中性粒细胞计数和细菌载量[3]。
nNIF peptide (10 mg/kg；腹腔注射；2 次给药) 作为辅助治疗方案，可将接受亚剂量 Meropenem 的盲肠匀浆诱导感染性腹膜炎新生小鼠的存活率显著提升至 83-100%[3]。
nNIF peptide (10 mg/kg；腹腔注射；2 次给药) 可将盲肠浆液诱导感染性腹膜炎新生小鼠的存活率显著提升至 18%[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss Webster (male, 8 weeks old, 25-27 grams, CLP-induced polymicrobial sepsis)[2]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 1 mg/kg
Administration: i.v.; 2 doses at 4 and 10 hours after CLP
Result: Achieved 30% 6-day survival rate and showed minimal improvement in illness severity scores compared to vehicle control at 0.1 mg/kg.
Achieved 70% 6-day survival rate, improved illness severity scores at 48 hours compared to vehicle control, decreased peritoneal fluid and plasma MPO-DNA complexes (NET formation) compared to vehicle/scrambled peptide control, increased peritoneal fluid and whole blood aerobic bacterial CFUs compared to vehicle/scrambled peptide control, and decreased peritoneal fluid TNF-α levels compared to vehicle/scrambled peptide/meropenem groups at 0.5 mg/kg.
Achieved 73% 6-day survival rate, improved illness severity scores at 24 and 48 hours compared to vehicle control, decreased peritoneal fluid and plasma MPO-DNA complexes (NET formation) compared to vehicle/scrambled peptide/meropenem groups, significantly decreased peritoneal fluid neutrophil CD11b expression compared to scrambled peptide control, increased peritoneal fluid and whole blood aerobic bacterial CFUs compared to vehicle/scrambled peptide control, and decreased peritoneal fluid TNF-α levels compared to vehicle/scrambled peptide/meropenem groups at 1 mg/kg.
Animal Model: Swiss Webster (male, 8 weeks old, 25-27 grams, CLP-induced polymicrobial sepsis with suboptimal antibiotic treatment)[2]
Dosage: 1 mg/kg (nNIF); 8 mg/kg (meropenem)
Administration: i.v. (nNIF; 2 doses at 4 and 10 hours after CLP); i.p. (meropenem; 2 initial doses at 4 and 10 hours after CLP then daily for 6 days)
Result: Achieved 90% 6-day survival rate (compared to 40% with suboptimal meropenem alone and 30% with suboptimal meropenem + scrambled peptide).
Improved illness severity scores at 24 and 48 hours compared to vehicle control.
Decreased peritoneal fluid bacterial CFUs at 96 hours compared to nNIF alone or meropenem alone groups.
Showed whole blood bacterial CFUs at 96 hours equivalent to meropenem alone levels (after being elevated at 24 hours compared to other groups).
Animal Model: outbred Swiss Webster mice (7-10-day-old, cecal slurry-induced infectious peritonitis)[3]
Dosage: 10 mg/kg
Administration: i.p.; 2 doses (1 h pre-cecal slurry injection and 4 h post-cecal slurry injection)
Result: Significantly decreased peritoneal MPO-DNA complex levels at 24 hours post-cecal slurry injection.
Significantly reduced peritoneal fluid levels of TNF-α, CXCL1, and IL-6 at 24 hours post-cecal slurry injection.
Significantly decreased circulating platelet-neutrophil aggregates at 24 hours post-cecal slurry injection.
Significantly increased peritoneal neutrophil counts at 24 hours post-cecal slurry injection compared to nNIF-SCR controls.
Significantly increased aerobic bacterial colony forming units in peritoneal fluid compared to nNIF-SCR controls.
Resulted in a 47% survival rate over 6 days, which was significantly higher than the 9% survival rate of nNIF-SCR treated mice.
Combination treatment with 10 mg/kg nNIF and 5 mg/kg meropenem significantly improved survival to 83% compared to 29% survival with 5 mg/kg meropenem alone.
Combination treatment with 10 mg/kg nNIF and 10 mg/kg meropenem significantly improved survival to 100% compared to 40% survival with 10 mg/kg meropenem alone.
Animal Model: outbred Swiss Webster mice (7-10-day-old, cecal slurry-induced infectious peritonitis)[3]
Dosage: 10 mg/kg
Administration: i.p.; 2 doses (2 h post-cecal slurry injection and 6 h post-cecal slurry injection)
Result: Delayed nNIF treatment alone resulted in an 18% survival rate, which was significantly higher than the survival rate of nNIF-SCR treated mice.
Combination treatment with 10 mg/kg nNIF and 10 mg/kg meropenem resulted in 100% survival, which was significantly higher than the 48% survival rate with 10 mg/kg meropenem alone.
分子量

3384.02

Formula

C158H248N38O40S2
CAS 号
Sequence

Lys-Phe-Asn-Lys-Pro-Phe-Val-Phe-Leu-Met-Ile-Glu-Gln-Asn-Thr-Lys-Ser-Pro-Leu-Phe-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln
Sequence Shortening

KFNKPFVFLMIEQNTKSPLFMGKVVNPTQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

nNIF peptide 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

nNIF peptide1644397-65-8Otherspolymorphonuclear leukocytespro-inflammatory cytokineCD11bE. coliCOVID-19 acute respiratory distress syndromemurine polymicrobial sepsisplatelet-neutrophil aggregatesneutrophil extracellular trapSwiss Webster miceneonatal infectious peritonitisInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
nNIF peptide
目录号：
HY-P11791
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z